I am pleased to announce that Frances (Fran) M. Zipp has been selected by the Board of Directors of Lachman Consultant Services to be President effective March 3, 2014. Roy Sturgeon who preceded Fran Zipp as President retired from the position effective January 2014 and now serves as Senior Advisor. Fran Zipp is responsible for all consulting operations and reports to Paul Vogel, Chief Executive Officer. Fran Zipp brings a wealth of innovator and generic pharmaceutical industry operational and management experience to this position aftermore than 30 years in the pharmaceutical industry. Key positions she has held include Group Executive Vice President and Global Head of Quality for Teva Pharmaceuticals, Senior Vice President of Quality at Wyeth Pharmaceuticals, Senior Vice President of Quality at Barr Pharmaceuticals, Head of U.S. Quality of Novartis (Ciba) and Chief Operating Officer at AAPI Pharma Sciences. In recent years Fran Zipp has been active in the pharmaceutical industrial and regulatory environment in the areas of Quality Metrics and Drug Shortages. She has worked closely with the FDA and international regulatory bodies, as well as with industry leaders to develop andadvance strategies for improving the assurance of drug product quality and safety. In 2013, she was elected to the Board of Directors for the International Society of Pharmaceutical Engineers (ISPE). On behalf of Lachman Consultants, we welcome Fran for a long, successful, and exciting career at our firm. For more than 30 years, Lachman Consultants has been the leader in providing cost-effective consultation and remediation services to the worldwide pharmaceutical, biotechnology, biologic, medical device, diagnostic and dietary supplement industries. With its strong and extensive cadre of consultant specialists and an unparalleled management team, its Compliance, Science & Technology, and Regulatory Practices provide the most expert counsel and array of services available. Lachman Consultants is proud of its tradition of supporting industry efforts to develop and ensure safe, effective and high-quality medical products. It remains committed to helping the industry anticipate and address its challenges through the development and implementation of practical, sustainable and cost-effective solutionsbased on the integration of scientific principles, evolving regulatory expectations, and technology.

Leon Lachman, Ph.D.

Chairman of the Board